This Month in JAAD International: May 2024: Randomized controlled trials, within-patient controls, and end points - 11/04/24
Doi : 10.1016/j.jaad.2024.02.038
Jonathan Kantor, MD, MSc, MSCE ⁎ 
Department of Dermatology, Center for Global Health, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, and Florida Center for Dermatology, St Augustine, Florida
∗Correspondence to: Jonathan Kantor, MD, MSc, MSCE, Florida Center for Dermatology, 1301 Plantation Island Dr S, St Augustine, FL 32080.Florida Center for Dermatology1301 Plantation Island Dr SSt AugustineFL32080
Key words : botulinum toxin, bromhidrosis, hyperhidrosis, individualized treatment, microwave thermolysis, osmidrosis, personalized therapy, PROMs, QoL, randomized controlled trial, RCT
Il testo completo di questo articolo è disponibile in PDF.
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
© 2024
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 90 - N° 5
P. 932 - maggio 2024 Ritorno al numero
Articolo precedente
- This Month in JAAD Case Reports: May 2024 Mycobacterium lepromatosis in Wisconsin
- Brett Sloan
- Getting JAKed up about deep vein thrombosis risk
- Warren R. Heymann
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?